Kilian Keetz

Kilian Keetz

Auto-generated profile, based on publicly available information

Kilian Keetz

I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2026 in Communications Medicine
Verified
Journal Article
Open access
PDF file
SCSophia Cichutek
Sophia Cichutek
LCLeon Cords
Leon Cords
KKKilian Keetz
Kilian Keetz
MHMarissa Herrmann
Marissa Herrmann
LLLiz J. Lam
Liz J. Lam
JWJulian Schulze zur Wiesch
Julian Schulze zur Wiesch
Background: Fibrinogen-like protein 1 (FGL-1), primarily secreted by the liver, modulates immune responses and is upregulated in patients with hepatocellular carcinoma. FGL-1 affects T-cell function by interacting with lymphocyte-activation gene 3 (LAG-3), and blocking this interaction can enhance T-cell activity, making it a potential therapeutic target. In coronavirus disease 2019 (COVID-19), the upregulation of immune checkpoints on T cells, particularly LAG-3, is associated with disease severity. Liver inflammation and damage are well-known features of COVID-19 pathogenesis; however, little is known about FGL-1 expression patterns in COVID-19 and other infectious diseases. Methods: In a cohort of 65 patients with COVID-19 and 33 healthy donors, plasma FGL-1 levels were measured, and their correlations with clinical parameters and the course of the disease were evaluated. Additionally, both bulk and severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2)-specific T-cell immune phenotypes, as well as SARS-CoV-2-specific immune responses were comprehensively characterized and measured using multicolor flow cytometry and pMHC multimer technology. Results: Plasma FGL-1 levels were elevated in patients with COVID-19 and correlated with IL-6 and disease severity. LAG-3 was significantly upregulated on bulk and COVID-19-specific CD8 + T cells and was co-expressed with T-cell activation markers (CD38, HLA-DR) and inhibitory receptors (PD-1, TIGIT). Conclusion: These findings suggest a role for FGL-1 in the pathogenesis of COVID-19, potentially through modulation of T-cell activation and function via LAG-3, and may also be relevant in other hyperinflammatory conditions where immune modulation plays a role.

13 November 2026 in Viruses
Verified
Journal Article
Open access
PDF file
JGJakob Groß
Jakob Groß
LMLukas Middendorf
Lukas Middendorf
Sven PischkeSven Pischke
Sven Pischke
IBIoannis Belios
Ioannis Belios
KKKilian Keetz
Kilian Keetz
JWJulian Schulze zur Wiesch
Julian Schulze zur Wiesch
Bepirovirsen achieved a functional cure in 19–20% of nucleos(t)ide analogue (NUC)-treated participants in the phase 3 B-Well trials. These trials enrolled patients with baseline quantitative hepatitis B surface antigen (qHBsAg) levels >100–≤ 3000 IU/mL, but the potential reach of this treatment in routine care remains uncertain. We evaluated 706 patients with chronic hepatitis B monoinfection at a German tertiary-care center. qHBsAg levels were ≤100, >100–≤1000, >1000–≤3000, and >3000 IU/mL in 145/706 (20.5%), 175/706 (24.8%), 142/706 (20.1%), and 244/706 (34.6%) patients, respectively. Overall, 317/706 (44.9%) patients fell within the B-Well qHBsAg window. Of these, 109/317 (34.4%) were receiving NUC therapy; among the remaining 208 untreated patients, 23/208 (11.1%) met an operationalized EASL 2025 indication for NUC initiation. The primary implementation scenario therefore comprised 132/706 (18.7%) patients. Excluding patients with identifiable B-Well trial exclusion proxies in a sensitivity analysis reduced this number to 102/706 (14.4%). Applying stratum-specific B-Well response rates of 26.0% and 7.3% yielded hypothetical functional cure rates of 17.2% (approximately 23 modeled functional cures) in the primary scenario and 16.1% (approximately 16 modeled functional cures) in the restricted scenario. These findings estimate the potential clinical reach of bepirovirsen and associated hypothetical functional cure outcomes at our center, highlighting the absence of current NUC therapy as a key factor limiting its implementation.